Healthcare Industry News: Express2
News Release - March 20, 2007
Boston Scientific Announces Schedule for ACC 2007Company to host analyst meeting and symposium on drug-eluting stents
NATICK, Mass., March 20 (HSMN NewsFeed) -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's major events and press announcements at the annual American College of Cardiology (ACC) Scientific Session and i2 Summit, which runs from March 24 to 27 in New Orleans.
"We expect the most recent clinical data on the TAXUS® Express2(TM) Coronary Stent will further reinforce its market-leading position," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "With the recent addition of our Everolimus-based PROMUS(TM) Stent, we are the first company to offer complementary drug-eluting stent technologies to satisfy a broader range of physician's preferred treatment methods." (PROMUS is a private-labeled XIENCE(TM) V Everolimus Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific.)
Schedule of Events (all times are CT)
Saturday, March 24
-- Spirit III Trial Results -- XIENCE V (PROMUS) Stent and TAXUS Stent. At 11:30 a.m., results from Abbott's Spirit III clinical trial will be presented by Gregg W. Stone, M.D. at a Late Breaking trial session in room La Nouvelle Orleans C. Dr. Stone will provide an analysis of eight and nine-month data on 1,002 patients treated with the XIENCE V (PROMUS) Stent or the TAXUS Express2 Stent. SPIRIT III is a large- scale, non-inferiority, U.S. pivotal trial. The Company plans to issue a press release at this time.
Sunday, March 25
-- TAXUS Meta-Analysis update. Results from the four-year TAXUS Stent meta-analysis will be presented in an e-poster session at 11:00 a.m. by Dr. Stone in Hall H. The independent meta-analysis will report data on the TAXUS stent from the TAXUS I, II, IV, V and VI trials that studied more than 3,500 patients. The Company plans to issue a press release at this time.
-- ARRIVE I Registry data. The Company will release two-year results from its ARRIVE I registry, which has enrolled nearly 2,600 consecutive patients at 50 sites in the United States. The program is designed to collect and analyze "real-world" safety and clinical outcomes data from the TAXUS Express2 paclitaxel-eluting stent system in the treatment of patients with coronary artery disease. The results will be presented by John M. Lasala, M.D., PhD, FACC, at 12:00 p.m. at an e- poster session in Hall H. The Company plans to issue a press release at this time.
-- TAXUS V ISR Results. The Company will release two-year results from the TAXUS V In-Stent Restenosis (ISR) clinical trial, which evaluates the TAXUS Express2 paclitaxel-eluting coronary stent system versus vascular brachytherapy for the treatment of bare-metal stent in-stent restenosis. The TAXUS V ISR trial is a prospective, randomized, open- label trial that has enrolled 396 patients at 37 sites in the U.S. The results will be presented by Stephen G. Ellis, M.D., at 2:30 p.m. at a poster session in Hall H. The Company plans to issue a press release at this time.
-- Symposium on Drug-Eluting Stents. From 8:00-9:15 p.m., the Company will host a symposium entitled, "Boston Scientific Leadership in Three Dimensions" in Ballroom D of the Hilton New Orleans Riverside, Two Poydras Street, New Orleans. The symposium will include presentations by Dr. Stone (Understanding the 2007 DES Clinical Data Landscape), Donald S. Baim, M.D., James B. Hermiller, M.D., FACC, FSCAI, and Dr. Lasala (PCI Patient Management), and Martin B. Leon, M.D. (Drug-Eluting Stent Evolution). The Company will also host a reception prior to the symposium at 7:00 p.m.
Monday, March 26
-- BTK-CHILL 12-month data. At 7:30 a.m., Tony S. Das, M.D., will present 12-month results from the Below-The-Knee (BTK) CHILL trial in a podium session. This prospective, multi-center trial is designed to evaluate the PolarCath(TM) Peripheral Dilatation System for restoring blood flow and reducing amputation in patients with critical limb ischemia. The Company plans to issue a press release at this time.
-- Analyst Meeting. From 7:30-9:00 a.m., the Company will host an analyst meeting in Ballroom D of the Hilton New Orleans Riverside, Two Poydras Street, New Orleans. The meeting is open to the media. Registration is required for admittance. This meeting is being webcast and can be accessed at Boston Scientific's website, www.bostonscientific.com. Please visit the website for details on how to access the webcast. A replay of the webcast will be archived and available in the Webcast and Archives section of the Investor Relations site at www.bostonscientific.com.
Boston Scientific will present its latest innovations at booth #3733 in the Exhibit Hall, including its drug-eluting stent and carotid stent technologies, and LATITUDE® Remote Patient Management system for implantable cardiac device patients. The booth will also include a physician resource and patient education area as well as interactive product displays.
PROMUS, TAXUS, Express and Express2 are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott. The SPIRIT Clinical Program is sponsored by Abbott. The PROMUS Stent is not approved for sale in the U.S.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.
Source: Boston Scientific
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBoston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX(TM) LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option
Boston Scientific Announces Acquisition of Obsidio, Inc.
Boston Scientific Announces Agreement to Purchase Majority Stake of M.I.Tech Co., Ltd from Synergy Innovation Co., Ltd